Who makes Anshen Buxin Liuwei Pill?

Anshen Buxin Liuwei Pill is developed by China Academy of Chinese Medical Sciences.

What development phase is Anshen Buxin Liuwei Pill in?

Anshen Buxin Liuwei Pill is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Anshen Buxin Liuwei Pill

China Academy of Chinese Medical Sciences · FDA-approved active Small molecule Quality 0/100

Anshen Buxin Liuwei Pill, developed by the China Academy of Chinese Medical Sciences, is a marketed traditional Chinese medicine with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Anshen Buxin Liuwei Pill
Sponsor	China Academy of Chinese Medical Sciences
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Anshen Buxin Liuwei Pills for the Treatment of Cardiac Neurosis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Anshen Buxin Liuwei Pill CI brief — competitive landscape report
Anshen Buxin Liuwei Pill updates RSS · CI watch RSS
China Academy of Chinese Medical Sciences portfolio CI